Alterity Therapeutics Ltd

ATH

Company Profile

  • Business description

    Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

  • Contact

    350 Collins Street
    Suite 4, Level 14
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.
stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,092.7025.500.28%
CAC 408,373.48139.561.69%
DAX 4025,405.34143.700.57%
Dow JONES (US)49,590.2086.130.17%
FTSE 10010,136.7612.160.12%
HKSE26,608.48376.691.44%
NASDAQ23,733.9062.560.26%
Nikkei 22551,939.89822.631.61%
NZX 50 Index13,694.681.57-0.01%
S&P 5006,977.2710.990.16%
S&P/ASX 2008,759.4025.800.30%
SSE Composite Index4,165.2944.861.09%

Market Movers